Symbols / EDSA Stock $5.37 -1.65% Edesa Biotech, Inc.

Healthcare • Biotechnology • Canada • NCM
EDSA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Pardeep Nijhawan FRCPC, M.D.
Exch · Country NCM · Canada
Market Cap 47.75M
Enterprise Value 46.12M
Income -10.44M
Sales —
FCF (ttm) -3.96M
Book/sh 0.20
Cash/sh 1.12
Employees 17
Insider 10d —
IPO Jun 21, 2010
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E —
PEG —
P/S —
P/B 26.20
P/C —
EV/EBITDA -4.23
EV/Sales —
Quick Ratio 4.67
Current Ratio 4.76
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.31
EPS next Y —
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-05-14
ROA -47.73%
ROE -81.16%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 8.89M
Shs Float 5.54M
Insider Own 18.87%
Instit Own 36.48%
Short Float 2.67%
Short Ratio 0.23
Short Interest 218.60K
52W High 20.32
vs 52W High -73.57%
52W Low 0.72
vs 52W Low 645.83%
Beta 1.07
Impl. Vol. —
Rel Volume 0.36
Avg Volume 842.57K
Volume 301.49K
Target (mean) $14.00
Tgt Median $14.00
Tgt Low $9.00
Tgt High $19.00
# Analysts 2
Recom None
Prev Close $5.46
Price $5.37
Change -1.65%
About

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$14.00
Mean price target
2. Current target
$5.37
Latest analyst target
3. DCF / Fair value
$-8.02
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.37
Low
$9.00
High
$19.00
Mean
$14.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-03 reit HC Wainwright & Co. Buy → Buy $5
2025-03-13 reit HC Wainwright & Co. Buy → Buy $21
News
RSS: Latest EDSA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-01 NIJHAWAN PARDEEP Chief Executive Officer — 1,671 $0.00 $0
2026-05-27 OLSON CHARLES V Director — 19,000 $0.00 $0
2026-05-27 NIJHAWAN PARDEEP Chief Executive Officer — 96,913 $0.00 $0
2026-05-27 MACDONALD SEAN ARTHUR Director — 19,000 $0.00 $0
2026-05-27 BROOKS MICHAEL J PH.D. President — 64,609 $0.00 $0
2026-05-27 SISTILLI CARLO Director — 19,000 $0.00 $0
2026-05-27 MARSHALL PATRICK Director — 19,000 $0.00 $0
2026-05-27 CHYPYHA JOAN Director — 19,000 $0.00 $0
2026-05-27 LIU DA DAVID Director — 19,000 $0.00 $0
2026-05-27 WEILER PETER JOHN Chief Financial Officer — 64,609 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Cost Of Revenue
—
—
—
—
Reconciled Cost Of Revenue
—
—
—
—
Gross Profit
—
—
—
—
Operating Expense
7.13
+12.84%
6.32
-26.91%
8.64
-50.87%
17.59
Research And Development
3.67
+27.30%
2.88
-39.89%
4.79
-64.05%
13.34
Selling General And Administration
4.24
+2.66%
4.13
-6.67%
4.43
-12.06%
5.04
General And Administrative Expense
4.24
+2.66%
4.13
-6.67%
4.43
-12.06%
5.04
Other Gand A
4.24
+2.66%
4.13
-6.67%
4.43
-12.06%
5.04
Other Operating Expenses
-0.78
-12.26%
-0.70
-20.18%
-0.58
+25.53%
-0.78
Total Expenses
7.13
+12.84%
6.32
-26.91%
8.64
-50.87%
17.59
Operating Income
-7.13
-12.84%
-6.32
+26.91%
-8.64
+50.87%
-17.59
Total Operating Income As Reported
-7.91
-12.78%
-7.01
+23.94%
-9.22
+49.80%
-18.37
EBITDA
-7.01
-14.32%
-6.13
+27.52%
-8.46
+51.59%
-17.47
Normalized EBITDA
-6.95
-13.74%
-6.11
+27.58%
-8.44
+51.66%
-17.45
Reconciled Depreciation
0.12
-35.89%
0.19
+1.41%
0.18
+55.24%
0.12
EBIT
-7.13
-12.84%
-6.32
+26.91%
-8.64
+50.87%
-17.59
Total Unusual Items
-0.06
-183.29%
-0.02
+3.22%
-0.02
-2.97%
-0.02
Total Unusual Items Excluding Goodwill
-0.06
-183.29%
-0.02
+3.22%
-0.02
-2.97%
-0.02
Net Income
-7.19
-16.46%
-6.17
+26.32%
-8.37
+52.28%
-17.55
Pretax Income
-7.18
-16.46%
-6.17
+26.33%
-8.37
+52.28%
-17.55
Net Non Operating Interest Income Expense
0.00
-98.33%
0.15
-47.04%
0.29
+356.29%
0.06
Net Interest Income
0.00
-98.33%
0.15
-47.04%
0.29
+356.29%
0.06
Interest Income Non Operating
0.00
-98.33%
0.15
-47.04%
0.29
+356.29%
0.06
Interest Income
0.00
-98.33%
0.15
-47.04%
0.29
+356.29%
0.06
Other Income Expense
-0.06
-849.79%
-0.01
+71.13%
-0.02
-2.97%
-0.02
Other Non Operating Income Expenses
—
0.01
—
—
Gain On Sale Of Security
-0.06
-183.29%
-0.02
+3.22%
-0.02
-2.97%
-0.02
Tax Provision
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
-62.50%
0.00
+52.61%
0.00
Tax Effect Of Unusual Items
-0.01
-183.29%
-0.00
+63.71%
-0.01
-57.15%
-0.01
Net Income Including Noncontrolling Interests
-7.19
-16.46%
-6.17
+26.32%
-8.37
+52.28%
-17.55
Net Income From Continuing Operation Net Minority Interest
-7.19
-16.46%
-6.17
+26.32%
-8.37
+52.28%
-17.55
Net Income From Continuing And Discontinued Operation
-7.19
-16.46%
-6.17
+26.32%
-8.37
+52.28%
-17.55
Net Income Continuous Operations
-7.19
-16.46%
-6.17
+26.32%
-8.37
+52.28%
-17.55
Normalized Income
-7.13
-15.97%
-6.15
+26.42%
-8.36
+52.31%
-17.53
Net Income Common Stockholders
-7.19
-16.46%
-6.17
+26.32%
-8.37
+52.28%
-17.55
Diluted EPS
-1.27
+34.20%
-1.93
+34.13%
-2.93
+60.14%
-7.35
Basic EPS
-1.27
+34.20%
-1.93
+34.13%
-2.93
+60.14%
-7.35
Basic Average Shares
5.68
+77.54%
3.20
+11.84%
2.86
+20.11%
2.38
Diluted Average Shares
5.68
+77.54%
3.20
+11.84%
2.86
+20.11%
2.38
Diluted NI Availto Com Stockholders
-7.19
-16.46%
-6.17
+26.32%
-8.37
+52.28%
-17.55
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Assets
13.53
+254.76%
3.81
-57.10%
8.89
-23.20%
11.58
Current Assets
11.51
+587.08%
1.68
-73.97%
6.44
-29.20%
9.09
Cash Cash Equivalents And Short Term Investments
10.79
+940.39%
1.04
-80.65%
5.36
-24.39%
7.09
Cash And Cash Equivalents
10.79
+940.39%
1.04
-80.65%
5.36
-24.39%
7.09
Receivables
0.64
+137.30%
0.27
-56.76%
0.63
-50.09%
1.26
Accounts Receivable
0.64
+137.30%
0.27
-56.76%
0.63
-50.09%
1.26
Prepaid Assets
—
—
—
0.75
Other Current Assets
0.08
-78.81%
0.37
-18.16%
0.45
-39.79%
0.75
Total Non Current Assets
2.02
-5.65%
2.14
-12.85%
2.45
-1.22%
2.48
Net PPE
0.00
-100.00%
0.02
-81.65%
0.10
+221.18%
0.03
Gross PPE
0.00
-100.00%
0.02
-87.24%
0.14
+103.63%
0.07
Accumulated Depreciation
—
-0.05
-19.85%
-0.04
-10.95%
-0.04
Properties
—
—
—
0.00
Buildings And Improvements
—
—
—
0.02
Machinery Furniture Equipment
—
0.05
+0.00%
0.05
+0.64%
0.05
Other Properties
—
0.02
-79.91%
0.09
+394.84%
0.02
Goodwill And Other Intangible Assets
1.98
-4.87%
2.08
-4.64%
2.18
-4.44%
2.28
Other Intangible Assets
1.98
-4.87%
2.08
-4.64%
2.18
-4.44%
2.28
Non Current Prepaid Assets
0.04
-2.88%
0.04
-76.28%
0.17
+1.18%
0.17
Total Liabilities Net Minority Interest
1.08
-41.15%
1.83
-0.48%
1.84
-15.69%
2.18
Current Liabilities
1.08
-41.15%
1.83
+0.60%
1.82
-14.90%
2.14
Payables And Accrued Expenses
1.08
-40.51%
1.81
+3.77%
1.75
-17.66%
2.12
Current Debt And Capital Lease Obligation
—
0.02
-73.41%
0.07
+293.75%
0.02
Current Capital Lease Obligation
0.00
-100.00%
0.02
-73.41%
0.07
+293.75%
0.02
Total Non Current Liabilities Net Minority Interest
0.00
0.00
-100.00%
0.02
-54.71%
0.04
Long Term Debt And Capital Lease Obligation
—
0.00
-100.00%
0.02
0.00
Long Term Capital Lease Obligation
—
0.00
-100.00%
0.02
0.00
Tradeand Other Payables Non Current
—
—
0.00
-100.00%
0.04
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
12.45
+528.52%
1.98
-71.89%
7.05
-24.94%
9.39
Common Stock Equity
3.19
+61.11%
1.98
-71.89%
7.05
-24.94%
9.39
Capital Stock
63.78
+35.01%
47.24
+1.27%
46.64
+9.82%
42.47
Common Stock
54.52
+15.41%
47.24
+1.27%
46.64
+9.82%
42.47
Preferred Stock
9.26
0.00
—
—
Share Issued
7.14
+119.92%
3.25
+5.59%
3.08
+29.21%
2.38
Ordinary Shares Number
7.14
+119.92%
3.25
+5.59%
3.08
+29.21%
2.38
Additional Paid In Capital
14.75
+8.66%
13.58
+4.12%
13.04
+16.67%
11.18
Retained Earnings
-65.91
-12.50%
-58.59
-11.77%
-52.42
-19.01%
-44.04
Gains Losses Not Affecting Retained Earnings
-0.17
+31.67%
-0.24
-13.03%
-0.21
-0.49%
-0.21
Other Equity Adjustments
-0.17
+31.67%
-0.24
-13.03%
-0.21
-0.49%
-0.21
Total Equity Gross Minority Interest
12.45
+528.52%
1.98
-71.89%
7.05
-24.94%
9.39
Total Capitalization
12.45
+528.52%
1.98
-71.89%
7.05
-24.94%
9.39
Working Capital
10.43
+6737.41%
-0.16
-103.41%
4.61
-33.61%
6.95
Invested Capital
3.19
+61.11%
1.98
-71.89%
7.05
-24.94%
9.39
Total Debt
0.00
-100.00%
0.02
-78.97%
0.09
+397.96%
0.02
Capital Lease Obligations
0.00
-100.00%
0.02
-78.97%
0.09
+397.96%
0.02
Net Tangible Assets
10.47
+10821.65%
-0.10
-102.01%
4.87
-31.52%
7.11
Tangible Book Value
1.21
+1342.78%
-0.10
-102.01%
4.87
-31.52%
7.11
Other Equity Interest
—
—
—
-0.21
Preferred Stock Equity
9.26
—
—
—
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Operating Cash Flow
-7.32
-49.73%
-4.89
+26.31%
-6.64
+45.95%
-12.28
Cash Flow From Continuing Operating Activities
-7.32
-49.73%
-4.89
+26.31%
-6.64
+45.95%
-12.28
Net Income From Continuing Operations
-7.19
-16.46%
-6.17
+26.32%
-8.37
+52.28%
-17.55
Depreciation Amortization Depletion
0.12
-35.89%
0.19
+1.41%
0.18
+55.24%
0.12
Depreciation And Amortization
0.12
-35.89%
0.19
+1.41%
0.18
+55.24%
0.12
Other Non Cash Items
—
-0.01
—
—
Stock Based Compensation
0.73
+35.75%
0.54
-56.88%
1.25
-44.86%
2.26
Change In Working Capital
-0.99
-272.60%
0.57
+85.41%
0.31
-89.35%
2.89
Change In Receivables
-0.38
-206.08%
0.36
-36.68%
0.56
-72.24%
2.03
Change In Prepaid Assets
0.11
-45.30%
0.20
-34.62%
0.30
+1646.41%
-0.02
Change In Payables And Accrued Expense
-0.72
-4167.65%
0.02
+103.16%
-0.56
-163.01%
0.88
Investing Cash Flow
—
—
0.00
+100.00%
-0.01
Cash Flow From Continuing Investing Activities
—
—
0.00
+100.00%
-0.01
Net PPE Purchase And Sale
—
—
0.00
+100.00%
-0.01
Purchase Of PPE
—
—
0.00
+100.00%
-0.01
Sale Of PPE
—
—
—
—
Capital Expenditure
—
—
—
-0.01
Net Investment Purchase And Sale
—
—
—
—
Purchase Of Investment
—
—
—
—
Sale Of Investment
—
—
—
—
Net Intangibles Purchase And Sale
—
—
—
—
Purchase Of Intangibles
—
—
—
—
Financing Cash Flow
17.03
+2776.69%
0.59
-87.74%
4.83
-58.47%
11.63
Cash Flow From Continuing Financing Activities
17.03
+2776.69%
0.59
-87.74%
4.83
-58.47%
11.63
Net Issuance Payments Of Debt
0.00
+100.00%
-0.03
0.00
—
Issuance Of Debt
—
—
—
—
Repayment Of Debt
0.00
+100.00%
-0.03
0.00
—
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
—
-0.03
0.00
—
Net Long Term Debt Issuance
—
-0.03
0.00
—
Short Term Debt Payments
0.00
+100.00%
-0.03
—
—
Net Short Term Debt Issuance
0.00
+100.00%
-0.03
—
—
Net Common Stock Issuance
7.72
+958.10%
0.73
-83.21%
4.35
-63.66%
11.96
Proceeds From Stock Option Exercised
-0.02
0.00
-100.00%
0.77
0.00
Net Other Financing Charges
-0.54
-404.63%
-0.11
+62.23%
-0.29
+12.99%
-0.33
Changes In Cash
9.71
+325.88%
-4.30
-137.95%
-1.81
-175.64%
-0.66
Effect Of Exchange Rate Changes
0.05
+278.42%
-0.03
-133.71%
0.08
+182.63%
-0.09
Beginning Cash Position
1.04
-80.65%
5.36
-24.39%
7.09
-9.55%
7.84
End Cash Position
10.79
+940.39%
1.04
-80.65%
5.36
-24.39%
7.09
Free Cash Flow
-7.32
-49.73%
-4.89
+26.31%
-6.64
+45.98%
-12.28
Common Stock Issuance
7.72
+958.10%
0.73
-83.21%
4.35
-63.66%
11.96
Issuance Of Capital Stock
17.60
+2312.77%
0.73
-83.21%
4.35
-63.66%
11.96
Net Preferred Stock Issuance
9.88
0.00
—
—
Preferred Stock Issuance
9.88
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category